The frantic search for a cure or prophylactic treatment of COVID-19 has
unfortunately led to a dropping of the guard of many medical specialists
resulting in widespread adoption of unproven treatment modalities. The
recent article regarding the inconsistent physician attitudes towards
hydroxychloroquine paints a depressing picture of the actual practices
during the so-called era of evidence-based medicine. On this backdrop,
we comment on how Romania (where this survey took place) has imposed
some of the most severe lockdown measures in Europe, including the
forced hospitalization of all confirmed with SARS-CoV-2 infection.
Additionally, a therapeutic guideline was written into law, endorsing
concomitant use of several drugs with unproven antiviral efficiency.
This unprecedented situation has resulted in the sometimes
indiscriminate prescription of off-label drugs, with a non-negligible
risk of adverse reactions, especially in fragile patients with
coexisting conditions. In light of the experience accrued in a COVID-19
dedicated unit, the authors discuss the importance of avoiding
polypharmacy and administering all antiviral drugs within the confines
of rigorously conducted clinical trials.